Plasma cholesterol is hyperresponsive to statin in ABCG5/ABCG8 transgenic mice

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Hepatology

• Publication date

  2006-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/hep.21380PMID 17058264
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abcg5/Abcg8-independent pathways contribute to hepatobiliary cholesterol secretion in mice.

  2006cited by this paper
• Cholesterol-regulated Translocation of NPC1L1 to the Cell Surface Facilitates Free Cholesterol Uptake*

  2006cited by this paper
• Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I.

  2005cited by this paper
• Hepatic expression of ABC transporters G5 and G8 does not correlate with biliary cholesterol secretion in liver transplant patients

  2005cited by this paper
• Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.

  2005cited by this paper
• Inactivation of NPC1L1 Causes Multiple Lipid Transport Defects and Protects against Diet-induced Hypercholesterolemia*

  2005cited by this paper
• ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin

  2004cited by this paper
• ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin Published, JLR Papers in Press, January 1, 2004. DOI 10.1194/jlr.M300278-JLR200

  2004cited by this paper
• Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management.

  2004cited by this paper
• Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver*

  2004cited by this paper
• Lowering plasma cholesterol by raising ldl receptors. 1981.

  2004cited by this paper
• ABCG5 and ABCG8 Are Obligate Heterodimers for Protein Trafficking and Biliary Cholesterol Excretion*

  2003cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• Regulation of ATP-binding Cassette Sterol Transporters ABCG5 and ABCG8 by the Liver X Receptors α and β*

  2002cited by this paper
• Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta.

  2002cited by this paper
• Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol.

  2002cited by this paper
• Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary

  2002cited by this paper
• Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion

  2002cited by this paper
• Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8.

  2002cited by this paper
• The genetic basis of variability in drug responses

  2002cited by this paper
• Baseline intestinal absorption and synthesis of cholesterol regulate its response to hypolipidaemic treatments in coronary patients.

  2002cited by this paper
• Identification of genes differentially expressed in breast cancer cells treated with tamoxifen, using microarray-based expression profiling

  2001cited by this paper
• Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis.

  2001cited by this paper
• Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption

  2001cited by this paper
• Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol.

  2000cited by this paper
• PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA

  2000cited by this paper
• Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters.

  2000cited by this paper
• Evidence for a Niemann-pick C (NPC) gene family: identification and characterization of NPC1L1.

  2000cited by this paper
• Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

  1998cited by this paper
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

  1998cited by this paper
• Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.

  1997cited by this paper
• 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion.

  1997cited by this paper
• Role of cholesterol in regulating apolipoprotein B secretion by the liver.

  1996cited by this paper
• Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat.

  1996cited by this paper
• The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

  1996cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

  1995cited by this paper
• Simvastatin decreases the hepatic secretion of very‐low‐density lipoprotein apolipoprotein B‐100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications

  1995cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease.

  1993cited by this paper
• The discovery and development of HMG-CoA reductase inhibitors.

  1992cited by this paper
• 39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor.

  1991cited by this paper
• Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.

  1990cited by this paper
• Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B‐containing lipoproteins

  1990cited by this paper
• Increased sitosterol absorption, decreased removal, and expanded body pools compensate for reduced cholesterol synthesis in sitosterolemia with xanthomatosis.

  1989cited by this paper
• Receptor-mediated endocytosis: concepts emerging from the LDL receptor system.

  1985cited by this paper
• Lowering plasma cholesterol by raising LDL receptors.

  1981cited by this paper
• Phytosterolaemia, xanthomatosis and premature atherosclerotic arterial disease: a case with high plant sterol absorption, impaired sterol elimination and low cholesterol synthesis

  1980cited by this paper
• Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase.

  1980cited by this paper
• Effects of ML-236B on cholesterol metabolism in mice and rats: Lack of hypocholesterolemic activity in normal animals

  1979cited by this paper
• Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals.

  1979cited by this paper
• Materials and Methods Figs. S1 to S4 Tables S1 and S2 References Niemann-pick C1 like 1 Protein Is Critical for Intestinal Cholesterol Absorption

  year unknowncited by this paper

• Targeting Lysophosphatidic Acid Ameliorates Dyslipidemia in Familial Hypercholesterolemia

  2025cites this paper
• The Hypocholesterolemic Potential of the Edible Algae Fucus vesiculosus: Proteomic and Quantitative PCR Analysis

  2023cites this paper
• Hepatic NPC1L1 overexpression attenuates alcoholic autophagy in mice

  2019cites this paper
• Infant Formula Feeding Increases Hepatic Cholesterol 7α Hydroxylase (CYP7A1) Expression and Fecal Bile Acid Loss in Neonatal Piglets.

  2018cites this paper
• Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model

  2017cites this paper
• Cholesterol Absorption Inhibitor Ezetimibe: Risk–Benefits and Role in Treating Dyslipidemias

  2015cites this paper
• Alterations of plant sterols, lathosterol, oxidative stress and inflammatory markers after the combination therapy of ezetimibe and statin drugs in type 2 diabetic patients.

  2015cites this paper
• Genetic demonstration of intestinal NPC1L1 as a major determinant of hepatic cholesterol and blood atherogenic lipoprotein levels.

  2014cites this paper
• Hypercholesterolemia induces angiogenesis and accelerates growth of breast tumors in vivo.

  2014cites this paper
• Atorvastatin induces bile acid-synthetic enzyme Cyp7a1 by suppressing FXR signaling in both liver and intestine in mice[S]

  2014cites this paper
• Atherosclerosis: lessons from LXR and the intestine

  2013cites this paper
• Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men

  2011cites this paper
• Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport.

  2011cites this paper
• Protein mediators of sterol transport across intestinal brush border membrane.

  2010influential citation
• NPC1L1 and cholesterol transport

  2010cites this paper
• Efflux and uptake transporters as determinants of statin response

  2010cites this paper
• Dietary cholesterol reverses resistance to diet-induced weight gain in mice lacking Niemann-Pick C1-Like 1[S]

  2010cites this paper
• Transporters as Drug Targets: Discovery and Development of NPC1L1 Inhibitors

  2010cites this paper
• The role of Niemann-Pick C1-Like 1 (NPC1L1) protein in cholesterol transport and metabolic diseases

  2010cites this paper
• NPC 1 L 1 and cholesterol transport

  2010cites this paper
• Opposing Gatekeepers of Apical Sterol Transport: Niemann-Pick C1-Like 1 (NPC1L1) and ATP-Binding Cassette Transporters G5 and G8 (ABCG5/ABCG8).

  2009cites this paper
• Chlordecone increased subcellular distribution of scavenger receptor class B type II to murine hepatic microsomes without altering cytosolic cholesterol binding proteins.

  2009cites this paper
• Quality Control of Low-Density DNA Microarrays

  2008cites this paper
• Niemann-Pick C1-Like 1 Is Required for an LXR Agonist to Raise Plasma HDL Cholesterol in Mice

  2008cites this paper
• The structure and function of Niemann–Pick C1-like 1 protein

  2008cites this paper